Carole Nuechterlein - Jun 17, 2021 Form 4 Insider Report for Aligos Therapeutics, Inc. (ALGS)

Role
Director
Signature
/s/ Lucinda Y. Quan, as attorney-in fact for Carole Nuechterlein
Stock symbol
ALGS
Transactions as of
Jun 17, 2021
Transactions value $
$0
Form type
4
Date filed
6/17/2021, 05:09 PM
Next filing
Oct 28, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALGS Stock Option (Right to Buy) Award $0 +15K $0.00 15K Jun 17, 2021 Common Stock 15K $26.58 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day prior to the annual meeting in 2022 of the Issuer's stockholders, assuming continuous service as a director until such vesting date.